ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

TARA vs STRO // OPERATING MARGIN

Protara Therapeutics Inc. (NASDAQ) VS. Sutro Biopharma Inc. (NASDAQ) • 15-METRIC TALLY: TARA 2 — STRO 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TARA VS. STRO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC TARA STRO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -34.70% -35.00% +0.30 TARA /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin ACTIVE — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 65.20% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 4/9 -2.00 STRO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 38.3 25.2 +13.14 TARA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $148.9M $151.6M -$2.6M STRO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR TARA REV STRO REV TARA GROSS % STRO GROSS % TARA FCF STRO FCF
FY 2025 $0 $102.5M — — -$56.5M -$177.2M
FY 2024 $0 $62.0M — — -$35.9M -$191.5M
FY 2023 $0 $153.7M — — -$37.6M -$111.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TARA // BETA —
STRO // BETA —